Navigation Links
PDL BioPharma Inc. Announces Exchange Offer for Its 2.875% Convertible Senior Notes Due February 15, 2015

INCLINE VILLAGE, Nev., Nov. 15, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: PDLI) today announced it has commenced an offer to exchange up to $180,000,000 in aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (Old Notes), for a like principal amount of new 2.875% Series 2011 Convertible Senior Notes due 2015 (New Notes), and a cash payment. Holders that exchange their Old Notes will receive a like principal amount of New Notes plus an exchange fee of $2.50 per $1,000 principal amount of their Old Notes validly tendered and accepted for exchange.


The terms of the New Notes will be substantially the same as the terms of the Old Notes, except that the New Notes will contain a "net share settlement feature" that will require PDL to settle the conversion value of the New Notes, determined over a 40-trading day measurement period after the conversion date, in cash and shares of PDL common stock, rather than exclusively in shares of PDL common stock as currently required by the Old Notes. Certain changes have been made to the settlement procedures and the anti-dilution provisions of the New Notes in order to accommodate the effects of this net share settlement feature and the conversion value measurement period. Also, clarifying language was added to the anti-dilution provisions in conformity with PDL's 3.75% Convertible Senior Notes due 2015, which also convert on a net share settlement basis. The New Notes also have restrictions on when they may be converted that did not apply to the conversion of the Old Notes. The offer is not contingent upon any minimum tender of Old Notes.

The exchange offer will expire at 5:00 p.m., New York City time, on December 13, 2011, unless extended or earlier terminated by PDL. Old Notes must be tendered on or prior to the expiration of the offer, and tendered Old Notes may be withdrawn at any time on or prior to the expiration of the offer. Validly withdrawn Old Notes will be returned to the holder in accordance with the terms of the offer. Following the expiration of the offer and subject to the terms of the offer, PDL will accept all Old Notes validly tendered and not validly withdrawn prior to the expiration of the offer and will issue the New Notes and pay the exchange fee promptly thereafter.

The information agent for the exchange offer is Georgeson, Inc. Holders of Old notes who have questions or would like additional copies of the exchange offer documents may call the information agent, Georgeson Inc., at (866) 541-3547.  Banks and brokers should call Georgeson at (212) 440-9800.

This description of the exchange offer is only a summary and is qualified in its entirety by all of the terms and conditions of the exchange offer set forth in the Offering Memorandum, Letter of Transmittal and other materials relating to the exchange offer, all as filed with the Securities and Exchange Commission. Neither PDL's Board of Directors nor any other person makes any recommendation as to whether holders of Old Notes should choose to tender and exchange their Old Notes for New Notes, and no one has been authorized to make such a recommendation. The Company's has been advised by JMP Securities LLC in connection with this exchange offer.

The issuance of the New Notes will not be registered under the Securities Act of 1933, as amended, in reliance on an exemption from registration thereunder.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. For more information, please visit

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-Looking Statements

This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

  • PDL's ability to protect its patent and other intellectual property rights through litigation or other means;
  • PDL's ability to acquire new patents and the cost thereof;
  • the validity and enforceability of PDL's supplementary protection certificates;
  • continued market acceptance of products sold by PDL's licensees upon which it receives royalties, approval of their licensed products that are in development and continued performance by our licensees of their obligations under their agreements with PDL;
  • the ability of PDL's licensees to maintain or obtain regulatory approvals;
  • changes in the third-party reimbursement environment;
  • expiration of PDL's existing patents;
  • the payment of dividends or distributions to PDL's stockholders;
  • failure to meet securities analyst or investor expectations;
  • delisting from the NASDAQ Global Select Market;
  • fluctuation in revenues and operating results;
  • fluctuations in foreign currency exchange rates;
  • PDL's ability to attract, retain and integrate key employees;
  • PDL's ability to collect under our indemnification rights from Abbott Biotherapeutics Corp. (fka Facet Biotech Corporation);
  • entry into acquisitions or other material royalty asset transactions that may not produce anticipated royalty revenues; and
  • errors in royalty payment calculations and other factors beyond PDL's control.

Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the SEC, including the "Risk Factors" section of its annual and quarterly reports filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference
3. PDL BioPharma Announces Third Quarter 2011 Financial Results
4. Planet Biopharmaceuticals, Inc. Divests Assets of Allergy Control Products, Inc.
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
6. PDL BioPharma to Announce Third Quarter 2011 Financial Results on November 9, 2011
7. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
8. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
9. Sentry BioPharma Services Earns a GSA Federal Supply Schedule Contract #GS-10F-0432X
10. Genesis Biopharma Signs Worldwide License Agreement with the NIH for Adoptive Cell Therapy to Treat a Variety of Cancers
11. Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
Post Your Comments:
(Date:10/9/2015)... LAUSANNE , Schweiz, October 9, 2015 Der ... geht an Dr.   Yutaka Kondo und Dr.   ... JCA-Mauvernay Award   2015 " geht an Dr.   ... --> Der " JCA-Mauvernay Award   ... und Dr.   Junko Takita    ™ ...
(Date:10/8/2015)... England and PITTSBURGH , ... ), a leading global pharmaceutical company, will host a ... at 5:00 pm ET to review the value ... (NYSE: PRGO ; TASE) through Mylan,s offer to ... a comprehensive presentation which outlines the compelling proposition for ...
(Date:10/8/2015)... , Oct. 8, 2015  The National Heart, ... $40 million to the Broad Institute of MIT ... of 20,000 individuals, as well as data to ... profiling. Trans-Omics for Precision Medicine ... toward a larger initiative, which will use whole ...
Breaking Medicine Technology:
... Cephalon, Inc. (Nasdaq: CEPH ) today provided notice ... Notes due 2014 (the "2014 Notes") and 2.00 percent ... in respect of the Merger (as defined below) of ... Industries Ltd., an Israeli corporation ("Parent"), the consummation of ...
... The Plasma Protein Therapeutics Association (PPTA) ... temporary and proposed regulations implementing the ... and fails to take into account concerns expressed ... narrow definition of an "orphan drug" disproportionally affects ...
Cached Medicine Technology:
(Date:10/9/2015)... Orleans, LA (PRWEB) , ... October 09, 2015 ... ... with offices serving New Orleans and the surrounding communities, is initiating a combined ... and medical care for unwanted animals in southern Louisiana. , Animal Rescue ...
(Date:10/9/2015)... Nedlands, WA, Australia (PRWEB) , ... October 09, ... ... be featured in an upcoming episode of Innovations with Ed Begley Jr., airing ... In this segment, Innovations will educate audiences on MMJ Phytotech Limited (MMJ) – ...
(Date:10/9/2015)... ... 2015 , ... Ryan Fox, the founder and CEO of ... says the latest figures on the state’s sales of legalized marijuana acknowledge that ... , Last month, according to the website , Colorado's Department ...
(Date:10/9/2015)... ... , ... Most people assume that Chinese food is more nutritious than American ... T’ai Chi Master and integrative medicine guru Steven Aung, MD agrees with that assessment, ... that they potentially complement one another, with each supplying nutritional elements the other may ...
(Date:10/9/2015)... TAMPA, Florida (PRWEB) , ... October 09, 2015 , ... A variety of race options ... Integrated Treatment of Co-occurring Disorders on Sunday, October 18, at Al Lopez Park, 4810 North ... a.m. and will include the choice of a 5K run or walk and a one-mile ...
Breaking Medicine News(10 mins):
... provide access to expensive new drugs. Canadian patients who ... are seeking to pay for these drugs within public ... Canadian Medical Association Journal ) (pre-embargo link only) ... Flood, Canada Research Chair in Health Law and Policy, ...
... ... FM & Me, - to find the most inspiring young users of FM technology. , ... Murten, Switzerland (PRWEB) February 11, 2009 -- Phonak, ... & Me , - in order to track down the most inspiring young users of FM ...
... CLEARWATER, Fla. , Feb. 8 Lincare Holdings Inc. (Nasdaq: ... year ended December 31, 2009 . , For the quarter ended ... compared with net revenues of $415.1 million for the fourth ... revenues in the fourth quarter of 2009 was comprised of 13% internal ...
... , PORT-AU-PRINCE, Haiti , Feb. 8 ... face more than just staggering physical needs such as food and shelter, ... humanitarian agency spoke to had lost loved ones--including friends, extended family or ... normal routines in order to recover, the Christian aid group ...
... PICK: Marker of Ewing sarcoma: potential new drug target? ... unknown cellular origin that affects children and young adults. The ... but its function in the disease is unknown. Now, Katia ... IRCCS, Bologna, Italy, have identified a crucial role for CD99 ...
... in patients with Alzheimer,s disease (latrepirdine) appears well tolerated ... individuals with Huntington,s disease, according to a report in ... one of the JAMA/Archives journals. "Huntington,s disease is ... cognition and leads to death within 20 years of ...
Cached Medicine News:
Ergotec Vetriretinal Instrument System. Extra fine angled tips (3 mm). 20 ga. shaft tapering to 23 ga., 10 mm from tip. Overall length from rear rotation knob to tip....
Ergotec Vetriretinal Instrument System. Reverse action jaws. 0.4 mm cupped tips....
Ultra-fine pick shape tips for grasping and manipulating membranes. Stationary distal jaw with black finish for reduced glare....
Ergotec Vetriretinal Instrument System. Ultra-fine 3.35 mm jaws. Angled 55 degrees. 20 gauge shaft. 30 mm in length. Blackened tip. Overall length from rear rotation knob to tip....
Medicine Products: